Therapeutic Drug Monitoring of Imatinib for Chronic Myeloid Leukemia Patients

doi 10.5772/27134
Full Text
Abstract

Available in full text

Date
Authors
Publisher

InTech

Related search

Therapeutic Drug Monitoring of Imatinib, Nilotinib, and Dasatinib for Patients With Chronic Myeloid Leukemia

Biological and Pharmaceutical Bulletin
MedicinePharmacologyPharmaceutical Science
2015English

Cost Effectiveness of Therapeutic Drug Monitoring for Imatinib Administration in Chronic Myeloid Leukemia

PLoS ONE
Multidisciplinary
2019English

The Development of Imatinib as a Therapeutic Agent for Chronic Myeloid Leukemia

Blood
BiochemistryImmunologyCell BiologyHematology
2005English

Gene Expression Signature of Primary Imatinib-Resistant Chronic Myeloid Leukemia Patients

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2006English

Molecular Monitoring of Therapeutic Milestones and Clinical Outcomes in Patients With Chronic Myeloid Leukemia

Cancer
Cancer ResearchOncology
2018English

Micro-Rna Response to Imatinib Mesylate in Patients With Chronic Myeloid Leukemia

Haematologica
Hematology
2010English

Imatinib and Plasmacytoid Dendritic Cell Function in Patients With Chronic Myeloid Leukemia

Blood
BiochemistryImmunologyCell BiologyHematology
2004English

Therapy of Chronic Myeloid Leukemia: Twilight of the Imatinib Era?

ISRN Oncology
2014English

Dasatinib in the Treatment of Imatinib Refractory Chronic Myeloid Leukemia

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy